personalized therapy
Recently Published Documents


TOTAL DOCUMENTS

579
(FIVE YEARS 162)

H-INDEX

37
(FIVE YEARS 10)

2022 ◽  
Vol 11 (1) ◽  
Author(s):  
Sofie Kirial Mørk ◽  
Mohammad Kadivar ◽  
Kalijn Fredrike Bol ◽  
Arianna Draghi ◽  
Marie Christine Wulff Westergaard ◽  
...  

Author(s):  
Monika Yadav ◽  
Nar Singh Chauhan ◽  
Bhavana Prasher ◽  
Mitali Mukerji

2021 ◽  
Vol 18 ◽  
Author(s):  
Claudio Napoli ◽  
Giuditta Benincasa ◽  
Samer Ellahham

Introduction: Diabetes mellitus (DM) comprises differential clinical phenotypes ranging from rare monogenic to common polygenic forms, such as type 1 (T1DM), type 2 (T2DM), and gestational diabetes, which are associated with cardiovascular complications. Also, the high-risk prediabetic state is rising worldwide, suggesting the urgent need for early personalized strategies to prevent and treat a hyperglycemic state. Objective: We aim to discuss the advantages and challenges of Network Medicine approaches in clarifying disease-specific molecular pathways, which may open novel ways for repurposing approved drugs to reach diabetes precision medicine and personalized therapy. Conclusion: The interactome [or protein-protein interactions (PPIs)] is a useful tool to identify subtle molecular differences between precise diabetic phenotypes and predict putative novel drugs. Despite being previously unappreciated as T2DM determinants, the growth factor receptor-bound protein 14 (GRB14), calmodulin 2 (CALM2), and protein kinase C-alpha (PRKCA) might have a relevant role in disease pathogenesis. Besides, in silico platforms have suggested that diflunisal, nabumetone, niflumic acid, and valdecoxib may be suitable for the treatment of T1DM; phenoxybenzamine and idazoxan for the treatment of T2DM by improving insulin secretion; and hydroxychloroquine reduce the risk of coronary heart disease (CHD) by counteracting inflammation. Network medicine has the potential to improve precision medicine in diabetes care and enhance personalized therapy. However, only randomized clinical trials will confirm the clinical utility of network-oriented biomarkers and drugs in the management of DM.


Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6233
Author(s):  
Shafia Rahman ◽  
Shimon Garrel ◽  
Michael Gerber ◽  
Radhashree Maitra ◽  
Sanjay Goel

Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor KRAS mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also have a negative prognostic impact on the overall survival. There is a growing unmet need for a personalized therapy approach for patients with KRAS-mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting KRAS- mutant CRC, while reviewing and elaborating on the discovery and physiology of KRAS.


2021 ◽  
Vol 5 (8) ◽  
Author(s):  
Francesca Palandri ◽  
Christian Di Pietro ◽  
Francesca Ricci ◽  
Pier Luigi Tazzari ◽  
Vanda Randi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document